{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:03:11Z","timestamp":1777071791292,"version":"3.51.4"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institutes of Health and the Substance Abuse and Mental Health Services Administration","award":["UM1DA049406"],"award-info":[{"award-number":["UM1DA049406"]}]},{"name":"National Institutes of Health and the Substance Abuse and Mental Health Services Administration","award":["UM1DA049406"],"award-info":[{"award-number":["UM1DA049406"]}]},{"name":"National Institutes of Health and the Substance Abuse and Mental Health Services Administration","award":["UM1DA049406"],"award-info":[{"award-number":["UM1DA049406"]}]},{"name":"National Institutes of Health and the Substance Abuse and Mental Health Services Administration","award":["UM1DA049406"],"award-info":[{"award-number":["UM1DA049406"]}]},{"name":"National Institutes of Health and the Substance Abuse and Mental Health Services Administration","award":["UM1DA049406"],"award-info":[{"award-number":["UM1DA049406"]}]},{"name":"National Institutes of Health and the Substance Abuse and Mental Health Services Administration","award":["UM1DA049406"],"award-info":[{"award-number":["UM1DA049406"]}]},{"name":"National Institutes of Health and the Substance Abuse and Mental Health Services Administration","award":["UM1DA049406"],"award-info":[{"award-number":["UM1DA049406"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Efforts to scale up overdose education and naloxone distribution (OEND), an evidence-based practice for reducing opioid overdose mortality, was a major focus of the HEALing Communities Study (HCS). The aim of this analysis is to describe the qualitative perspectives of partner organizations regarding the impacts of implementing OEND in a state that used a naloxone \u201chub with many spokes\u201d model for scaling up this strategy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Small group (<jats:italic>n<\/jats:italic>\u2009=\u200920) and individual (<jats:italic>n<\/jats:italic>\u2009=\u200924) qualitative interviews were conducted with staff from 44 agencies in eight Kentucky counties that implemented OEND from April 2020 to June 2022. Interviews were conducted between 6 and 8 months after the end of the intervention. Initial deductive coding used the reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) framework, and then additional inductive sub-coding focused on passages within the OEND Effectiveness code. Thematic analysis was then utilized to identify themes regarding the impacts of implementing OEND.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Participants identified multi-level impacts of implementing OEND. At the individual-level, participants described lives being saved, greater access to naloxone for individuals served by the agency, reduced stigma toward OEND by clients, and greater client-level self-efficacy to respond to overdoses. Organizational impacts included improved staff readiness for overdose response, enhanced clinical relationships between staff and clients, and reduced staff stigma. Participants described positive impacts on their organizational networks and clients\u2019 social networks. Community-level impacts included greater overall access and reduced stigma toward OEND.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These qualitative data revealed that staff from agencies involved in a community-wide effort to scale up OEND perceived multi-level benefits, including saving lives, reducing stigma, improving naloxone access, and enhancing staff and client readiness, while strengthening organizational and community networks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ClinicalTrials.gov, NCT04111939. Registered 30 September 2019, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04111939\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04111939<\/jats:ext-link>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-025-00553-2","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T03:58:39Z","timestamp":1741924719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Organizational perspectives on the impacts of scaling up overdose education and naloxone distribution in Kentucky"],"prefix":"10.1186","volume":"20","author":[{"given":"Hannah K.","family":"Knudsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Back-Haddix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaquita","family":"Andrews-Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas R.","family":"Oyler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon L.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"553_CR1","doi-asserted-by":"crossref","unstructured":"Spencer MR, Garnett MF, Mini\u00f1o AM. Drug overdose deaths in the United States, 2002\u20132022. Hyattsville, MD: National Center for Health Statistics; 2024. NCHS Data Brief, no 491.","DOI":"10.15620\/cdc:135849"},{"key":"553_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2105\/AJPH.2023.307550","volume":"114","author":"A Athey","year":"2024","unstructured":"Athey A, Kilmer B, Cerel J. An overlooked emergency: more than one in eight US adults have had their lives disrupted by drug overdose deaths. Am J Public Health. 2024;114:276\u20139.","journal-title":"Am J Public Health"},{"key":"553_CR3","doi-asserted-by":"publisher","first-page":"111062","DOI":"10.1016\/j.drugalcdep.2023.111062","volume":"255","author":"P Rock","year":"2024","unstructured":"Rock P, Slavova S, Westgate PM, Nakamura A, Walsh SL. Examination of Naloxone dosing patterns for opioid overdose by emergency medical services in Kentucky during increased Fentanyl use from 2018 to 2021. Drug Alcohol Depend. 2024;255:111062.","journal-title":"Drug Alcohol Depend"},{"key":"553_CR4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2105\/AJPH.2021.306256","volume":"111","author":"J Friedman","year":"2021","unstructured":"Friedman J, Akre S. COVID-19 and the drug overdose crisis: Uncovering the deadliest months in the united States, January\u2013July 2020. Am J Public Health. 2021;111:1284\u201391.","journal-title":"Am J Public Health"},{"key":"553_CR5","doi-asserted-by":"publisher","first-page":"e2116391","DOI":"10.1001\/jamanetworkopen.2021.16391","volume":"4","author":"S Slavova","year":"2021","unstructured":"Slavova S, Quesinberry D, Hargrove S, Rock P, Brancato C, Freeman PR, Walsh SL. Trends in drug overdose mortality rates in Kentucky, 2019\u20132020. JAMA Netw Open. 2021;4:e2116391.","journal-title":"JAMA Netw Open"},{"key":"553_CR6","doi-asserted-by":"publisher","first-page":"104122","DOI":"10.1016\/j.drugpo.2023.104122","volume":"119","author":"LK Blair","year":"2023","unstructured":"Blair LK, Howard J, Peiper NC, Little BB, Taylor KC, Baumgartner R, Creel L, DuPre NC. Residence in urban or rural counties in relation to opioid overdose mortality among Kentucky hospitalizations before and during the COVID-19 pandemic. Int J Drug Policy. 2023;119:104122.","journal-title":"Int J Drug Policy"},{"key":"553_CR7","doi-asserted-by":"crossref","unstructured":"Rao IJ, Humphreys K, Brandeau ML. Effectiveness of policies for addressing the US opioid epidemic: A model-based analysis from the Stanford-Lancet commission on the North American opioid crisis. Lancet Reg Health Am. 2021;3.","DOI":"10.1016\/j.lana.2021.100031"},{"key":"553_CR8","unstructured":"U.S. Department of Health and Human Services. Overdose prevention strategy. [https:\/\/www.hhs.gov\/overdose-prevention\/]. Accessed on February 24, 2023."},{"key":"553_CR9","doi-asserted-by":"publisher","first-page":"eabm8147","DOI":"10.1126\/sciadv.abm8147","volume":"8","author":"EJ Stringfellow","year":"2022","unstructured":"Stringfellow EJ, Lim TY, Humphreys K, DiGennaro C, Stafford C, Beaulieu E, Homer J, Wakeland W, Bearnot B, McHugh RK, et al. Reducing opioid use disorder and overdose deaths in the united States: A dynamic modeling analysis. Sci Adv. 2022;8:eabm8147.","journal-title":"Sci Adv"},{"key":"553_CR10","doi-asserted-by":"publisher","first-page":"109505","DOI":"10.1016\/j.drugalcdep.2022.109505","volume":"237","author":"JD Jones","year":"2022","unstructured":"Jones JD, Campbell AN, Brandt L, Metz VE, Martinez S, Wall M, Corbeil T, Andrews H, Castillo F, Neale J, et al. A randomized clinical trial of the effects of brief versus extended opioid overdose education on Naloxone utilization outcomes by individuals with opioid use disorder. Drug Alcohol Depend. 2022;237:109505.","journal-title":"Drug Alcohol Depend"},{"key":"553_CR11","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/add.13326","volume":"111","author":"R McDonald","year":"2016","unstructured":"McDonald R, Strang J. Are take-home Naloxone programmes effective? Systematic review utilizing application of the Bradford hill criteria. Addiction. 2016;111:1177\u201387.","journal-title":"Addiction"},{"key":"553_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/ADM.0000000000000034","volume":"8","author":"AK Clark","year":"2014","unstructured":"Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and Naloxone distribution programs. J Addict Med. 2014;8:153\u201363.","journal-title":"J Addict Med"},{"key":"553_CR13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2105\/AJPH.2021.306306","volume":"111","author":"A Razaghizad","year":"2021","unstructured":"Razaghizad A, Windle SB, Filion KB, Gore G, Kudrina I, Paraskevopoulos E, Kimmelman J, Martel MO, Eisenberg MJ. The effect of overdose education and Naloxone distribution: an umbrella review of systematic reviews. Am J Public Health. 2021;111:e1\u201312.","journal-title":"Am J Public Health"},{"key":"553_CR14","doi-asserted-by":"publisher","first-page":"109555","DOI":"10.1016\/j.drugalcdep.2022.109555","volume":"238","author":"LM Holmes","year":"2022","unstructured":"Holmes LM, Rishworth A, King BH. Disparities in opioid overdose survival and Naloxone administration in Pennsylvania. Drug Alcohol Depend. 2022;238:109555.","journal-title":"Drug Alcohol Depend"},{"key":"553_CR15","doi-asserted-by":"publisher","first-page":"107536","DOI":"10.1016\/j.drugalcdep.2019.06.038","volume":"204","author":"RB Naumann","year":"2019","unstructured":"Naumann RB, Durrance CP, Ranapurwala SI, Austin AE, Proescholdbell S, Childs R, Marshall SW, Kansagra S, Shanahan ME. Impact of a community-based Naloxone distribution program on opioid overdose death rates. Drug Alcohol Depend. 2019;204:107536.","journal-title":"Drug Alcohol Depend"},{"key":"553_CR16","doi-asserted-by":"publisher","first-page":"f174","DOI":"10.1136\/bmj.f174","volume":"346","author":"AY Walley","year":"2013","unstructured":"Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, Ruiz S, Ozonoff A. Opioid overdose rates and implementation of overdose education and nasal Naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.","journal-title":"BMJ"},{"key":"553_CR17","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/add.14664","volume":"114","author":"MA Irvine","year":"2019","unstructured":"Irvine MA, Kuo M, Buxton JA, Balshaw R, Otterstatter M, Macdougall L, Milloy MJ, Bharmal A, Henry B, Tyndall M, et al. Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic. Addiction. 2019;114:1602\u201313.","journal-title":"Addiction"},{"key":"553_CR18","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2105\/AJPH.2018.304590","volume":"108","author":"AL Pitt","year":"2018","unstructured":"Pitt AL, Humphreys K, Brandeau ML. Modeling health benefits and harms of public policy responses to the US opioid epidemic. Am J Public Health. 2018;108:1394\u2013400.","journal-title":"Am J Public Health"},{"key":"553_CR19","doi-asserted-by":"publisher","first-page":"109190","DOI":"10.1016\/j.drugalcdep.2021.109190","volume":"230","author":"A Chatterjee","year":"2022","unstructured":"Chatterjee A, Yan S, Xuan Z, Waye KM, Lambert AM, Green TC, Stopka TJ, Pollini RA, Morgan JR, Walley AY. Broadening access to Naloxone: community predictors of standing order Naloxone distribution in Massachusetts. Drug Alcohol Depend. 2022;230:109190.","journal-title":"Drug Alcohol Depend"},{"key":"553_CR20","doi-asserted-by":"publisher","first-page":"108759","DOI":"10.1016\/j.drugalcdep.2021.108759","volume":"225","author":"EN Kinnard","year":"2021","unstructured":"Kinnard EN, Bluthenthal RN, Kral AH, Wenger LD, Lambdin BH. The Naloxone delivery cascade: identifying disparities in access to Naloxone among people who inject drugs in Los Angeles and San Francisco, CA. Drug Alcohol Depend. 2021;225:108759.","journal-title":"Drug Alcohol Depend"},{"key":"553_CR21","doi-asserted-by":"publisher","first-page":"109668","DOI":"10.1016\/j.drugalcdep.2022.109668","volume":"241","author":"S Nolen","year":"2022","unstructured":"Nolen S, Zang X, Chatterjee A, Behrends CN, Green TC, Linas BP, Morgan JR, Murphy SM, Walley AY, Schackman BR, Marshall BDL. Evaluating equity in community-based Naloxone access among Racial\/ethnic groups in Massachusetts. Drug Alcohol Depend. 2022;241:109668.","journal-title":"Drug Alcohol Depend"},{"key":"553_CR22","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1186\/s12889-022-13741-5","volume":"22","author":"AL Spector","year":"2022","unstructured":"Spector AL, Galletly CL, Christenson EA, Montaque HDG, Dickson-Gomez J. A qualitative examination of Naloxone access in three States: Connecticut, Kentucky, and Wisconsin. BMC Public Health. 2022;22:1387.","journal-title":"BMC Public Health"},{"key":"553_CR23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1353\/hpu.2021.0107","volume":"32","author":"BE Meyerson","year":"2021","unstructured":"Meyerson BE, Moehling TJ, Agley JD, Coles HB, Phillips J. Insufficient access: Naloxone availability to laypeople in Arizona and Indiana, 2018. J Health Care Poor Underserved. 2021;32:819\u201329.","journal-title":"J Health Care Poor Underserved"},{"key":"553_CR24","doi-asserted-by":"publisher","first-page":"109259","DOI":"10.1016\/j.drugalcdep.2021.109259","volume":"231","author":"RA Pollini","year":"2022","unstructured":"Pollini RA, Ozga JE, Joyce R, Xuan Z, Walley AY. Limited access to pharmacy-based Naloxone in West Virginia: results from a statewide purchase trial. Drug Alcohol Depend. 2022;231:109259.","journal-title":"Drug Alcohol Depend"},{"key":"553_CR25","doi-asserted-by":"publisher","first-page":"108335","DOI":"10.1016\/j.drugalcdep.2020.108335","volume":"217","author":"HEALing Communities Study Consortium","year":"2020","unstructured":"HEALing Communities Study Consortium. The healing (Helping to end addiction Long-term SM) communities study: protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. Drug Alcohol Depend. 2020;217:108335.","journal-title":"Drug Alcohol Depend"},{"key":"553_CR26","doi-asserted-by":"publisher","first-page":"109804","DOI":"10.1016\/j.drugalcdep.2023.109804","volume":"245","author":"R Chandler","year":"2023","unstructured":"Chandler R, Nunes EV, Tan S, Freeman PR, Walley AY, Lofwall M, Oga E, Glasgow L, Brown JL, Fanucchi L, et al. Community selected strategies to reduce opioid-related overdose deaths in the healing (Helping to end addiction Long-term (SM)) communities study. Drug Alcohol Depend. 2023;245:109804.","journal-title":"Drug Alcohol Depend"},{"key":"553_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13722-023-00426-6","volume":"18","author":"HK Knudsen","year":"2023","unstructured":"Knudsen HK, Freeman PR, Oyler DR, Oser CB, Walsh SL. Scaling up overdose education and Naloxone distribution in Kentucky: adoption and reach achieved through a hub with many spokes model. Addict Sci Clin Pract. 2023;18:72.","journal-title":"Addict Sci Clin Pract"},{"key":"553_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","volume":"11","author":"JR Brooklyn","year":"2017","unstructured":"Brooklyn JR, Sigmon SC. Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact. J Addict Med. 2017;11:286\u201392.","journal-title":"J Addict Med"},{"key":"553_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fpubh.2019.00064","volume":"7","author":"RE Glasgow","year":"2019","unstructured":"Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, Ory MG, Estabrooks PA. RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-Year review. Front Public Health. 2019;7:64.","journal-title":"Front Public Health"},{"key":"553_CR30","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2105\/AJPH.89.9.1322","volume":"89","author":"RE Glasgow","year":"1999","unstructured":"Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89:1322\u20137.","journal-title":"Am J Public Health"},{"key":"553_CR31","doi-asserted-by":"publisher","first-page":"100207","DOI":"10.1016\/j.dadr.2023.100207","volume":"10","author":"DR Oyler","year":"2024","unstructured":"Oyler DR, Knudsen HK, Oser CB, Walsh SL, Roberts M, Nigam SR, Westgate PM, Freeman PR. Equity of overdose education and Naloxone distribution provided in the Kentucky healing communities study. Drug Alcohol Depend Rep. 2024;10:100207.","journal-title":"Drug Alcohol Depend Rep"},{"key":"553_CR32","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1017\/cts.2021.789","volume":"5","author":"JS Holtrop","year":"2021","unstructured":"Holtrop JS, Estabrooks PA, Gaglio B, Harden SM, Kessler RS, King DK, Kwan BM, Ory MG, Rabin BA, Shelton RC, Glasgow RE. Understanding and applying the RE-AIM framework: clarifications and resources. J Clin Transl Sci. 2021;5:e126.","journal-title":"J Clin Transl Sci"},{"key":"553_CR33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12913-018-2938-8","volume":"18","author":"JS Holtrop","year":"2018","unstructured":"Holtrop JS, Rabin BA, Glasgow RE. Qualitative approaches to use of the RE-AIM framework: rationale and methods. BMC Health Serv Res. 2018;18:177.","journal-title":"BMC Health Serv Res"},{"key":"553_CR34","doi-asserted-by":"crossref","unstructured":"Westafer LM, Beck SA, Simon C, Potee B, Soares WE, Schoenfeld EM. Barriers and facilitators to harm reduction for opioid use disorder: a qualitative study of people with lived experience. Ann Emerg Med. 2024;83:340\u2013350.","DOI":"10.1016\/j.annemergmed.2023.11.020"},{"key":"553_CR35","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/10826084.2023.2294968","volume":"59","author":"AB Collins","year":"2024","unstructured":"Collins AB, Kaplowitz E, Bastani P, McKee H, Whitaker D, Hallowell BD, McKenzie M. I don\u2019t go overboard: perceptions of overdose risk and risk reduction strategies among people who use drugs in Rhode Island. Subst Use Misuse. 2024;59:673\u20139.","journal-title":"Subst Use Misuse"},{"key":"553_CR36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12954-023-00900-z","volume":"20","author":"Z Kesich","year":"2023","unstructured":"Kesich Z, Ibragimov U, Komro K, Lane K, Livingston M, Young A, Cooper HLF. I\u2019m not going to Lay back and watch somebody die: a qualitative study of how people who use drugs\u2019 Naloxone experiences are shaped by rural risk environment and overdose education\/naloxone distribution intervention. Harm Reduct J. 2023;20:166.","journal-title":"Harm Reduct J"},{"key":"553_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/00220426221133024","volume":"53","author":"AA Urmanche","year":"2023","unstructured":"Urmanche AA, Harocopos A. Experiences administering Naloxone among people in different social roles: people who use opioids and family members and friends. J Drug Issues. 2023;53:475\u201389.","journal-title":"J Drug Issues"},{"key":"553_CR38","doi-asserted-by":"publisher","first-page":"10868","DOI":"10.4081\/qrmh.2023.10868","volume":"7","author":"I Natale","year":"2023","unstructured":"Natale I, Harvey C, Wood P, Anderson K. It can save your life, that\u2019s all I know, barriers and facilitators for engagement in take-home Naloxone for people receiving opioid substitution treatment in regional Australia: an explorative study. Qual Res Med Healthc. 2023;7:10868.","journal-title":"Qual Res Med Healthc"},{"key":"553_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13722-023-00395-w","volume":"18","author":"R French","year":"2023","unstructured":"French R, Holliday Davis M, Aronowitz SV, Crowe M, Abrams M, Edwards G, Lowenstein M. I wouldn\u2019t need Narcan for myself, but I can have it for somebody else: perceptions of harm reduction among hospitalized patients with OUD. Addict Sci Clin Pract. 2023;18:41.","journal-title":"Addict Sci Clin Pract"},{"key":"553_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12954-023-00805-x","volume":"20","author":"R Abadie","year":"2023","unstructured":"Abadie R. I don\u2019t want to die: a qualitative study of coping strategies to prevent fentanyl-related overdose deaths among people who inject drugs and its implications for harm reduction policies. Harm Reduct J. 2023;20:75.","journal-title":"Harm Reduct J"},{"key":"553_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12954-023-00772-3","volume":"20","author":"N Beharie","year":"2023","unstructured":"Beharie N, Urmanche A, Harocopos A. A mixed-methods analysis of risk-reduction strategies adopted by syringe services program participants and non-syringe services program participants in new York City. Harm Reduct J. 2023;20:38.","journal-title":"Harm Reduct J"},{"key":"553_CR42","doi-asserted-by":"crossref","unstructured":"Gray M, Shin SS, Silcox J, Flores D, Bolivar D, Irwin AN, Floyd AS, Bratberg J, Boggis JS, Hartung DM, Green TC. Like it was just everyday business: A qualitative study of pharmacy-based naloxone and syringe customer experience. J Am Pharm Assoc (2003). 2023;63:838\u2013846.","DOI":"10.1016\/j.japh.2023.01.013"},{"key":"553_CR43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10826084.2022.2136489","volume":"58","author":"KE Schneider","year":"2023","unstructured":"Schneider KE, Allen ST, Winiker AK, White RH, O\u2019Rourke A, Sherman SG, Grieb SM. Overdose experiences among people who inject drugs in West Virginia: personal loss, psychological distress, Naloxone, and Fentanyl. Subst Use Misuse. 2023;58:22\u20136.","journal-title":"Subst Use Misuse"},{"key":"553_CR44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12954-022-00677-7","volume":"19","author":"M Lowenstein","year":"2022","unstructured":"Lowenstein M, Sangha HK, Spadaro A, Perrone J, Delgado MK, Agarwal AK. Patient perspectives on Naloxone receipt in the emergency department: a qualitative exploration. Harm Reduct J. 2022;19:97.","journal-title":"Harm Reduct J"},{"key":"553_CR45","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/08901171221107908","volume":"37","author":"A Spadaro","year":"2023","unstructured":"Spadaro A, Agarwal AK, Sangha HK, Perrone J, Delgado MK, Lowenstein M. Motivation to carry Naloxone: A qualitative analysis of emergency department patients. Am J Health Promot. 2023;37:200\u20139.","journal-title":"Am J Health Promot"},{"key":"553_CR46","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1080\/08897077.2021.1915915","volume":"42","author":"J Ko","year":"2021","unstructured":"Ko J, Chan E, Doroudgar S. Patient perspectives of barriers to Naloxone obtainment and use in a primary care, underserved setting: A qualitative study. Subst Abus. 2021;42:1030\u20139.","journal-title":"Subst Abus"},{"key":"553_CR47","doi-asserted-by":"publisher","first-page":"e22411","DOI":"10.2196\/22411","volume":"4","author":"AS Bennett","year":"2020","unstructured":"Bennett AS, Freeman R, Des Jarlais DC, Aronson ID. Reasons people who use opioids do not accept or carry no-cost Naloxone: qualitative interview study. JMIR Form Res. 2020;4:e22411.","journal-title":"JMIR Form Res"},{"key":"553_CR48","doi-asserted-by":"publisher","first-page":"108030","DOI":"10.1016\/j.jsat.2020.108030","volume":"115","author":"M Kano","year":"2020","unstructured":"Kano M, Salvador JG, Katzman W, Sussman AL, Takeda MY. You\u2019ve got to care to carry this stuff community implications from take-home Naloxone use: A qualitative study. J Subst Abuse Treat. 2020;115:108030.","journal-title":"J Subst Abuse Treat"},{"key":"553_CR49","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/08897077.2020.1748165","volume":"43","author":"LS Kahn","year":"2022","unstructured":"Kahn LS, Wozniak M, Vest BM, Moore C. Narcan encounters: overdose and Naloxone rescue experiences among people who use opioids. Subst Abus. 2022;43:113\u201326.","journal-title":"Subst Abus"},{"key":"553_CR50","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1080\/10826084.2020.1735437","volume":"55","author":"A Kline","year":"2020","unstructured":"Kline A, Mattern D, Cooperman N, Dooley-Budsock P, Williams JM, Borys S. A blessing and a curse: opioid users\u2019 perspectives on Naloxone and the epidemic of opioid overdose. Subst Use Misuse. 2020;55:1280\u20137.","journal-title":"Subst Use Misuse"},{"key":"553_CR51","doi-asserted-by":"crossref","unstructured":"Irwin AN, Gray M, Ventricelli D, Boggis JS, Bratberg J, Floyd AS, Silcox J, Hartung DM, Green TC. I go out of my way to give them an extra smile now: A study of pharmacists who participated in respond to prevent, a community pharmacy intervention to accelerate provision of harm reduction materials. Res Social Adm Pharm.; 2024.","DOI":"10.1016\/j.sapharm.2024.02.001"},{"key":"553_CR52","doi-asserted-by":"crossref","unstructured":"Rawal S, Osae SP, Tackett RL, MacKinnon NJ, Soiro FD, Young HN. Community pharmacists\u2019 naloxone counseling: A theory-informed qualitative study. J Am Pharm Assoc (2003). 2023;63:1743\u20131752 e1742.","DOI":"10.1016\/j.japh.2023.08.018"},{"key":"553_CR53","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.japh.2021.06.004","volume":"61","author":"SC Ijioma","year":"2021","unstructured":"Ijioma SC, Fernandez EV, Gatewood SB, Carroll NV, Salgado TM. Community pharmacists in Virginia dispensing Naloxone under a standing order: A qualitative study. J Am Pharm Assoc (2003). 2021;61:753\u201360. e751.","journal-title":"J Am Pharm Assoc (2003)"},{"key":"553_CR54","doi-asserted-by":"publisher","first-page":"104160","DOI":"10.1016\/j.drugpo.2023.104160","volume":"120","author":"JJ Carroll","year":"2023","unstructured":"Carroll JJ, Cummins ER, Formica SW, Green TC, Bagley SM, Beletsky L, Rosenbloom D, Xuan Z, Walley AY. The Police paradox: A qualitative study of post-overdose outreach program implementation through public health-public safety partnerships in Massachusetts. Int J Drug Policy. 2023;120:104160.","journal-title":"Int J Drug Policy"},{"key":"553_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12954-023-00748-3","volume":"20","author":"D Lloyd","year":"2023","unstructured":"Lloyd D, Rowe K, Leung SJ, Pourtaher E, Gelberg K. It\u2019s just another tool on my toolbelt: new York state law enforcement officer experiences administering Naloxone. Harm Reduct J. 2023;20:29.","journal-title":"Harm Reduct J"},{"key":"553_CR56","doi-asserted-by":"publisher","first-page":"115230","DOI":"10.1016\/j.socscimed.2022.115230","volume":"309","author":"M Baumgart-McFarland","year":"2022","unstructured":"Baumgart-McFarland M, Chiarello E, Slay T. Reluctant rs: professional ambivalence, cultural imaginaries, and deservingness construction in Naloxone provision. Soc Sci Med. 2022;309:115230.","journal-title":"Soc Sci Med"},{"key":"553_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40352-022-00172-y","volume":"10","author":"HM Smiley-McDonald","year":"2022","unstructured":"Smiley-McDonald HM, Attaway PR, Richardson NJ, Davidson PJ, Kral AH. Perspectives from law enforcement officers who respond to overdose calls for service and administer Naloxone. Health Justice. 2022;10:9.","journal-title":"Health Justice"},{"key":"553_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12954-022-00664-y","volume":"19","author":"MC Frost","year":"2022","unstructured":"Frost MC, Austin EJ, Corcorran MA, Briggs ES, Behrends CN, Juarez AM, Frank ND, Healy E, Prohaska SM, LaKosky PA, et al. Responding to a surge in overdose deaths: perspectives from US syringe services programs. Harm Reduct J. 2022;19:79.","journal-title":"Harm Reduct J"},{"key":"553_CR59","doi-asserted-by":"publisher","first-page":"e240229","DOI":"10.1001\/jamanetworkopen.2024.0229","volume":"7","author":"L Fraimow-Wong","year":"2024","unstructured":"Fraimow-Wong L, Martin M, Thomas L, Giuliano R, Nguyen OK, Knight K, Suen LW. Patient and staff perspectives on the impacts and challenges of hospital-based harm reduction. JAMA Netw Open. 2024;7:e240229.","journal-title":"JAMA Netw Open"},{"key":"553_CR60","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/acem.14683","volume":"30","author":"C Sasson","year":"2023","unstructured":"Sasson C, Dieujuste N, Klocko R, Basrai Z, Celedon M, Hsiao J, Himstreet J, Hoffman J, Pfaff C, Malmstrom R, et al. Barriers and facilitators to implementing medications for opioid use disorder and Naloxone distribution in veterans affairs emergency departments. Acad Emerg Med. 2023;30:289\u201398.","journal-title":"Acad Emerg Med"},{"key":"553_CR61","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jen.2020.05.006","volume":"46","author":"BE Punches","year":"2020","unstructured":"Punches BE, Soliman S, Freiermuth CE, Lane BH, Lyons MS. Emergency nurse perceptions of Naloxone distribution in the emergency department. J Emerg Nurs. 2020;46:675\u201381. e671.","journal-title":"J Emerg Nurs"},{"key":"553_CR62","doi-asserted-by":"publisher","first-page":"108325","DOI":"10.1016\/j.drugalcdep.2020.108325","volume":"217","author":"T Winhusen","year":"2020","unstructured":"Winhusen T, Walley A, Fanucchi LC, Hunt T, Lyons M, Lofwall M, Brown JL, Freeman PR, Nunes E, Beers D, et al. The Opioid-overdose reduction continuum of care approach (ORCCA): Evidence-based practices in the healing communities study. Drug Alcohol Depend. 2020;217:108325.","journal-title":"Drug Alcohol Depend"},{"key":"553_CR63","doi-asserted-by":"crossref","unstructured":"Young AM, Brown JL, Hunt T, Sprague Martinez LS, Chandler R, Oga E, Winhusen TJ, Baker T, Battaglia T, Bowers-Sword R et al. Protocol for community-driven selection of strategies to implement evidence-based practices to reduce opioid overdoses in the HEALing Communities Study: a trial to evaluate a community-engaged intervention in Kentucky, Massachusetts, New York and Ohio. BMJ Open. 2022;12:e059328.","DOI":"10.1136\/bmjopen-2021-059328"},{"key":"553_CR64","doi-asserted-by":"publisher","first-page":"108326","DOI":"10.1016\/j.drugalcdep.2020.108326","volume":"217","author":"L Sprague Martinez","year":"2020","unstructured":"Sprague Martinez L, Rapkin BD, Young A, Freisthler B, Glasgow L, Hunt T, Salsberry PJ, Oga EA, Bennet-Fallin A, Plouck TJ, et al. Community engagement to implement evidence-based practices in the healing communities study. Drug Alcohol Depend. 2020;217:108326.","journal-title":"Drug Alcohol Depend"},{"key":"553_CR65","doi-asserted-by":"publisher","first-page":"108338","DOI":"10.1016\/j.drugalcdep.2020.108338","volume":"217","author":"RC Lefebvre","year":"2020","unstructured":"Lefebvre RC, Chandler RK, Helme DW, Kerner R, Mann S, Stein MD, Reynolds J, Slater MD, Anakaraonye AR, Beard D, et al. Health communication campaigns to drive demand for evidence-based practices and reduce stigma in the healing communities study. Drug Alcohol Depend. 2020;217:108338.","journal-title":"Drug Alcohol Depend"},{"key":"553_CR66","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/10810730.2023.2262948","volume":"28","author":"MD Stein","year":"2023","unstructured":"Stein MD, Krause C, Rodgers E, Silwal A, Helme D, Slater M, Beard D, Lewis N, Luster J, Stephens K, Lefebvre C. Lessons learned from developing tailored community communication campaigns in the healing communities study. J Health Commun. 2023;28:699\u2013705.","journal-title":"J Health Commun"},{"key":"553_CR67","doi-asserted-by":"crossref","unstructured":"HEALing Communities Study Consortium. Community-based cluster-randomized trial to reduce opioid overdose deaths. N Engl J Med. 2024;391:989\u20131001.","DOI":"10.1056\/NEJMoa2401177"},{"key":"553_CR68","doi-asserted-by":"crossref","unstructured":"Freeman PR, Walley AY, Winhusen TJ, Oga EA, Villani J, Hunt T, Chandler RK, Oyler DR, Reilly B, Gelberg K et al. Effect of the communities that HEAL intervention on overdose education and Naloxone distribution: A cluster randomized wait-list controlled trial. Am J Public Health. 2025;115:83\u201394.","DOI":"10.2105\/AJPH.2024.307845"},{"key":"553_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/16094069231165933","volume":"22","author":"AS McAlearney","year":"2023","unstructured":"McAlearney AS, Walker D, Shiu-Yee K, Crable E, Auritt V, Barkowski L, Batty E, Dasgupta A, Goddard-Eckrich D, Knudsen HK, et al. Embedding big qual and team science into qualitative research: lessons from a large-scale, cross-site research study. Int J Qualitative Methods. 2023;22:1\u20139.","journal-title":"Int J Qualitative Methods"},{"key":"553_CR70","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15:1277\u201388.","journal-title":"Qual Health Res"},{"key":"553_CR71","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19:349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"553_CR72","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3:77\u2013101.","journal-title":"Qualitative Res Psychol"},{"key":"553_CR73","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1080\/0142159X.2020.1755030","volume":"42","author":"ME Kiger","year":"2020","unstructured":"Kiger ME, Varpio L. Thematic analysis of qualitative data: AMEE guide 131. Med Teach. 2020;42:846\u201354.","journal-title":"Med Teach"},{"key":"553_CR74","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.cptl.2018.03.019","volume":"10","author":"A Castleberry","year":"2018","unstructured":"Castleberry A, Nolen A. Thematic analysis of qualitative research data: is it as easy as it sounds? Curr Pharm Teach Learn. 2018;10:807\u201315.","journal-title":"Curr Pharm Teach Learn"},{"key":"553_CR75","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/109019818801500401","volume":"15","author":"KR McLeroy","year":"1988","unstructured":"McLeroy KR, Bibeau D, Steckler A, Glanz K. An ecological perspective on health promotion programs. Health Educ Q. 1988;15:351\u201377.","journal-title":"Health Educ Q"},{"key":"553_CR76","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/10783903211050121","volume":"28","author":"K Werder","year":"2022","unstructured":"Werder K, Curtis A, Reynolds S, Satterfield J. Addressing bias and stigma in the Language we use with persons with opioid use disorder: A narrative review. J Am Psychiatr Nurses Assoc. 2022;28:9\u201322.","journal-title":"J Am Psychiatr Nurses Assoc"},{"key":"553_CR77","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1037\/adb0000830","volume":"37","author":"RL Brown","year":"2023","unstructured":"Brown RL, Batty E, Lofwall M, Kiviniemi M, Kizewski A. Opioid use-related stigma and health care decision-making. Psychol Addict Behav. 2023;37:222\u20137.","journal-title":"Psychol Addict Behav"},{"key":"553_CR78","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/ACM.0000000000005467","volume":"99","author":"E Magnan","year":"2024","unstructured":"Magnan E, Weyrich M, Miller M, Melnikow J, Moulin A, Servis M, Chadha P, Spivack S, Henry SG. Stigma against patients with substance use disorders among health care professionals and trainees and stigma-reducing interventions: A systematic review. Acad Med. 2024;99:221\u201331.","journal-title":"Acad Med"},{"key":"553_CR79","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","volume":"131","author":"LC van Boekel","year":"2013","unstructured":"van Boekel LC, Brouwers EP, van Weeghel J, Garretsen HF. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131:23\u201335.","journal-title":"Drug Alcohol Depend"},{"key":"553_CR80","doi-asserted-by":"publisher","first-page":"104241","DOI":"10.1016\/j.drugpo.2023.104241","volume":"122","author":"A Davis","year":"2023","unstructured":"Davis A, Stringer KL, Drainoni ML, Oser CB, Knudsen HK, Aldrich A, Surratt HL, Walker DM, Gilbert L, Downey DL, et al. Community-level determinants of stakeholder perceptions of community stigma toward people with opioid use disorders, harm reduction services and treatment in the healing communities study. Int J Drug Policy. 2023;122:104241.","journal-title":"Int J Drug Policy"},{"key":"553_CR81","doi-asserted-by":"publisher","first-page":"104435","DOI":"10.1016\/j.drugpo.2024.104435","volume":"128","author":"BD Rivera","year":"2024","unstructured":"Rivera BD, Friedman SR. What would it really take to solve the overdose epidemic in the united States? Int J Drug Policy. 2024;128:104435.","journal-title":"Int J Drug Policy"},{"key":"553_CR82","doi-asserted-by":"publisher","first-page":"e240132","DOI":"10.1001\/jamanetworkopen.2024.0132","volume":"7","author":"TJ Stopka","year":"2024","unstructured":"Stopka TJ, Babineau DC, Gibson EB, Knott CE, Cheng DM, Villani J, Wai JM, Blevins D, David JL, Goddard-Eckrich DA, et al. Impact of the communities that HEAL intervention on buprenorphine-waivered practitioners and buprenorphine prescribing: A prespecified secondary analysis of the HCS randomized clinical trial. JAMA Netw Open. 2024;7:e240132.","journal-title":"JAMA Netw Open"},{"key":"553_CR83","doi-asserted-by":"publisher","first-page":"111286","DOI":"10.1016\/j.drugalcdep.2024.111286","volume":"259","author":"L Glasgow","year":"2024","unstructured":"Glasgow L, Douglas C, Sprunger JG, Campbell ANC, Chandler R, Dasgupta A, Holloway J, Marks KR, Roberts SM, Martinez LS, et al. Effect of the communities that HEAL intervention on receipt of behavioral therapies for opioid use disorder: A cluster randomized wait-list controlled trial. Drug Alcohol Depend. 2024;259:111286.","journal-title":"Drug Alcohol Depend"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00553-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00553-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00553-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:32:32Z","timestamp":1741966352000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00553-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00553-2","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol (Pro00038088) was approved by Advarra Inc., the HEALing Communities Study single Institutional Review Board. All participants provided verbal informed consent prior to being interviewed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HKK, SAH, SBH, MG, OD, PRF, and DRO declare that they have no competing interests. SLW has served as a scientific advisor\/consultant for Opiant Pharmaceuticals and Pocket Naloxone.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}